Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zhejiang Yongtai Chiral Medicine Technology Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, STEADMAN, DAVID J. As the busiest examiner for the portfolio, STEADMAN, DAVID J is responsible for 1 busiest examiner pending action. This indicates that the company's current patent office activity is focused on a single matter under the review of a single individual.
The prosecution is occurring within 1 distinct art unit. The alignment of 1 pending office action, 1 distinct examiner, and 1 distinct art unit suggests a specific technical focus for the company in the Biotechnology & Pharmaceuticals sector. This concentration means that the 1 busiest examiner pending action represents the entirety of the company's current interaction with the patent office. There is no distribution of the workload across different examiners or art units.
For practitioners, the presence of 1 distinct examiner and 1 distinct art unit simplifies the tracking of the 1 pending office action. The outcome of this action is solely in the hands of STEADMAN, DAVID J. This focus within the Biotechnology & Pharmaceuticals technology area allows for a direct prosecution strategy, as the company only needs to navigate the requirements of 1 distinct art unit and the specific examination style of 1 distinct examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEADMAN, DAVID J | 1 | 57.7% | +29.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18863124 | OMEGA-TRANSAMINASE MUTANT AND APPLICATION THEREOF | STEADMAN, DAVID J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18863124 | OMEGA-TRANSAMINASE MUTANT AND APPLICATION THEREOF | STEADMAN, DAVID J | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18863124 | OMEGA-TRANSAMINASE MUTANT AND APPLICATION THEREOF | STEADMAN, DAVID J | 1652 | §103§112Other | Non-Final OA | — | Pending | Nov 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhejiang Yongtai Chiral Medicine Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David J Steadman has the most, with 1 of Zhejiang Yongtai Chiral Medicine Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
